Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MitoTempol for Vascular Function in Midlife Stress and MDD
NCT06466655Completed
- Sponsor
- University of Delaware
- Start
- May 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of mito-TEMPO in major depressive disorder (MDD) (2 arms), sponsored by University of Delaware. Primary endpoint: Nitric Oxide-Mediated Endothelium-dependent Dilation at Day 15. Started May 2024; status: completed.
02
Drugs
mito-TEMPO
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06466655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06466655.